Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2025
Archives
Alzheimer’s disease: An epidemic without a cure
Researchers are investigating the continued ineffectiveness of amyloid-targeting therapies which points to either flaws in the amyloid cascade hypothesis, or its application in drug development – but what can be done to help? And what can ARC do?
Arc: A therapeutic hub for Alzheimer’s disease
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by progressive memory loss and cognitive impairments. Therapy development has been driven almost exclusively by the amyloid hypothesis, which poses that AD is caused by the amyloid plaques seen in postmortem brains of patients. However, drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed.
Arc: A new target for treating alzheimer’s disease
Antonius M. VanDongen, Associate Professor from Duke University, walks us through Arc, a new target for treating Alzheimer’s disease.
